Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (July 2025)
33 slides from Inoviq's investor presentation, Jul 14, 2025
Slide 1: INOVIQ investor briefing: Key programs update
INOVIQ investor briefing Key programs update: EXO-OC and CAR-exosomes 14th July 2025 ASX: IIQ
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: Agenda
Agenda INOVIQ overview p4 EXO-OC test results p8 CAR-Exosomes in vitro data p16 Summary and Q&A p21 3
Slide 4: INOVIQ Overview: Next-generation diagnostics and therapeutics for cancer
INOVIQ Overview| Next-generation diagnostics and therapeutics for cancer Financial snapshot (ASX:IIQ) Market capitalisation A$41.9m Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Share price (11 July 2025) A$0.375 52-week H/L A$0.690-0.345 Exosome resear
Slide 5: Achievements & Catalysts: Building a leading exosome company
Achievements & Catalysts| Building a leading exosome company FY25 Achievements FY26 Catalysts 2-Year Objectives Partner diagnostic programs, INOVIQ established as a Expand exosome platform accelerate development of leading exosome company across research tools, exosome therapeutics and with best-in-
Slide 6: Strategic pillars: Driving growth and value across diagnostics & therapeutics
Strategic pillars| Driving growth and value across diagnostics & therapeutics 1 Exosome platform 2 Research tools 3 Diagnostics 4 Therapeutics Proprietary exosome Exosome isolation Exosome tests for Exosome therapeutics technology platform tools for biomarker screening, liquid to target and destroy
Slide 7: Products & pipeline: Staged research tools, diagnostics & therapeutics portfolio
Products & pipeline| Staged research tools, diagnostics & therapeutics portfolio • Product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical-stage CAR-exosome therapeutic program for solid tumours • Pipeline p
Slide 8: Exosome Diagnostics
Exosome Diagnostics Next-gen liquid biopsies and companion diagnostics 8
Slide 9: Ovarian Cancer screening is a significant unmet need
Ovarian Cancer screening is a significant unmet need Deadliest gynaecological cancer & 8th most 5-Year Survival following Diagnosis (UK)3 #1 common cancer in women 100% 95% 80% 60% 70% 325k New cases pa1 ~70% diagnosed at stage III or IV4 no approved 40% 45% test for early 20% 30% detection in asymp
Slide 10: What are exosomes and how are they revolutionizing health care?
What are exosomes and how are they revolutionizing health care? o Cells release EVs (including exosomes) that carry information from their parent cell o These EVs can interact with other cells, transferring this information to change the cell’s behaviour o INOVIQ’s proprietary technology leverages t
Slide 11: Exosome diagnostics: Ovarian cancer screening test
Exosome diagnostics| Ovarian cancer screening test • Australian exosome diagnostic innovation developed in a collaboration between INOVIQ and UQ1,2 • Poster presentation at ASCO 2025 titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test3 • Combines propriet
Slide 12: EXO-OC clinical validation study: EXO-NET isolated miRNA biomarkers
EXO-OC clinical validation study| EXO-NET isolated miRNA biomarkers Percent of Samples Correctly Identified by EXO-OC Study Design: Retrospective case-control study (n=497)1 • Biobanked plasma samples from age-matched normal healthy women, benign masses and ovarian cancers • Proprietary AI-enhanced
Slide 13: EXO-OC: Planned model validation studies
EXO-OC | Planned model validation studies Subject Details Group Samples Percent Percent Total Cancers Single-site, retrospective case-control blinded evaluation study to Healthy Controls 1400 69% Study Design confirm the performance of the EXO-OC test in 2040 plasma samples with performance compared
Slide 14: EXO-OC: Development & commercialisation roadmap
EXO-OC | Development & commercialisation roadmap Clinical & Regulatory Advice underway Multi-stage commercialisation strategy to ensure the rapid and 2025 broad availability of the EXO-OC test to women worldwide Partnering with high-complexity CLIA lab • Expanded analytical and clinical validation s
Slide 15: EXO-OC: Scalable, flexible workflow
EXO-OC | Scalable, flexible workflow Designed to integrate seamlessly with existing workflows and instruments in HT pathology labs EXO-NET Data Analysis Sample exosome RTqPCR & Clinical report isolation Interpretation Fast TAT Plasma Liquid Handling Robots: HT IVD platforms: Microlab STAR IVD (Hamil
Slide 16: Exosome Therapeutics
Exosome Therapeutics Next-gen acellular therapy to target and kill solid tumours 16
Slide 17: CAR-Exosomes: Target and destroy cancer cells
CAR-Exosomes| Target and destroy cancer cells CAR-EVs inherit the targeting and cytotoxic properties of their parent CAR-T or CAR-NK cells • CAR-EVs are produced by CAR-T/NK cells • CAR-EVs contains cytotoxic proteins (perforin, granzyme A,B,K FasL/TRAIL, granulysin, IFN-γ/TNF-α) • CAR-EVs interact
Slide 18: CAR-Exosomes: Targeted treatment for Triple-Negative Breast Cancer
CAR-Exosomes| Targeted treatment for Triple-Negative Breast Cancer • Unlike other breast cancer types there are no In Vitro effect of CAR-EVs on cell viability in TNBC cells approved targeted therapies available untreated • TNBC lacks the three most common drug targets for breast cancer treatment: e
Slide 19: CAR-Exosomes: Cost-effective process compared to Cell Therapy
CAR-Exosomes| Cost-effective process compared to Cell Therapy Cell Therapy next generation CAR-EV NK Therapy Centralised GMP Manufacturing Facility Reprogram to kill Grow enough cells for a cancer cells treatment dose Natural killer cell Reprogram exosome Immortalized cell bank Grow - unlimited Coll
Slide 20: CAR-Exosomes: Therapeutic development path
CAR-Exosomes| Therapeutic development path EXO-ACE In Vivo Selection First Patient CAR EV Isolation Studies of CRO Dose CAR-T / NK Cell In Vitro IND Regulatory Approval Development Studies Submission and Site Selection ✓Master cell ✓High purity & ✓In vitro PoC for ✓Peter Mac banks yield of CAR- CAR-
Slide 21: Summary and Q&A
Summary and Q&A es “S =INOVIQ
Slide 22: Summary: Positioned for growth
Summary| Positioned for growth Leading exosome company Exosome research tools Clinical-stage EXO-OC with proven technology partnered, on-market and screening test targeting platform and best-in-class generating initial revenue significant unmet need in research tools, diagnostics with potential for
Slide 23: Q&A Panel
Q&A Panel Dr Leearne Hinch BVMS MBA Prof Gregory Rice PhD MHA Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards BAcc CA Dr Emma Ball PhD MBA GAICD CFO & Company Secretary Chief Commercial Officer e. medwards@inoviq.com e. eball@inoviq.com INOVIQ L
Slide 24: Appendices
Appendices 4 “ SS ras ‘ _ ise ST 4 a =INOVIQ
Slide 25: Board: Capital markets, healthcare and biotech experience
Board| Capital markets, healthcare and biotech experience DAVID WILLIAMS MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Experienced biotechnology director and Healthcare industry director and Healthcare industry director and investment banker with ext
Slide 26: Leadership: Corporate, scientific, clinical and commercial expertise
Leadership| Corporate, scientific, clinical and commercial expertise MANAGEMENT DR LEEARNE HINCH BVMS MBA DR GREG RICE PhD MHA MARK EDWARDS BAcc CA EMMA BALL PhD MBA GAICD Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Chief Commercial Officer Biotechnology CEO with a prove
Slide 27: Ovarian Cancer in Major Markets
Ovarian Cancer in 9 Major Markets Market Incidence Prevalence Eligible Population General Annual 1 (5-year) (45-74yo) Screening Addressable 11 Participation Population 2 China 61,060 180,870 282,713,102 51.4% 145,201,449 3 USA 21,179 68,388 60,689,385 75.7% 45,941,864 4 Japan 10,693 33,732 24,907,72
Slide 28: Triple Negative Breast Cancer: Unmet need for effective targeted therapies
Triple Negative Breast Cancer| Unmet need for effective targeted therapies Percent of BC by Subtype4 2.3m Breast Cancer new cases pa1 HR-/HER2+ Unknown 4% 6% HR+/HER2+ 9% HR-/HER2- TNBC 15% TNBC is 10-15% of all breast cancer cases4 11% HR+/HER2- ~20% in women of 70% limited availability African anc
Slide 29: Breast Cancer in Major Markets: TNBC ~15% of cases
Breast Cancer in 9 Major Markets| TNBC ~15% of cases Market Incidence Prevalence TNBC 1,2 3 (5-year) incidence USA 274,375 1,194,271 179,141 China 357,161 1,160,496 174,074 Japan 91,916 389,650 58,448 Germany 74,016 313,465 47,020 France 65,659 271,977 40,797 UK 58,756 253,839 38,076 Italy 57,480 23
Slide 30: CAR-Exosomes: Potential advantages over autologous CAR-T therapy
CAR-Exosomes| Potential advantages over autologous CAR-T therapy Off-the- • Next-gen cell-free therapy to target and kill solid tumours shelf, allogenic • Versatile and flexible technology platform with multiple Stabile & therapy Multiple therapeutic applications easier to therapeutic manufacture ap
Slide 31: CAR-Exosomes: Planned in vivo study to evaluate anti-tumour efficacy in mouse model
CAR-Exosomes| Planned in vivo study to evaluate anti-tumour efficacy in mouse model Objective • Evaluate anti-tumour efficacy of CAR-NK EVs on a TNBC – immunodeficient mouse model (CDX) CAR NK EVs CAR NK Cells Methods • NSG mouse model MDA-MB-231 • Evaluate dose and time effects of CAR-EVs (and appr
Slide 32: Glossary
Glossary AUC area under the curve IVD in vitro diagnostic BC breast cancer KOL key opinion leader CA125 cancer antigen 125 biomarker (used in ovarian cancer) LDT laboratory developed test CA15-3 cancer antigen 15-3 biomarker (used in breast cancer) MIA in vitro multivariate index assay CAGR compound
Slide 33: Ovarian Cancer in Major Markets References
Ovarian Cancer in 9 Major Markets References 1. United Nations, Data Portal, Population Division, 2024 data 2. The Lancet, Volume 55, Special Issue 101426, February 2025 3. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021, CDC, https://www.cdc.gov/pcd/